Sanofi-Aventis (SNY): Low-risk potential

by Paul Tracy, editor High-Yield International

Paris-based pharmaceutical giant Sanofi-Aventis (SNY) is in the midst of a transformation.

With the bulk of the major patent expirations now behind it, investors are beginning to focus on the firm's ability to deliver on growth drivers in the form of new blockbuster drugs.